Reviewing Graybug Vision (NASDAQ:GRAY) and Hepion Pharmaceuticals (NASDAQ:HEPA)

Valuation & Earnings

This table compares Hepion Pharmaceuticals and Graybug Vision”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93 million	($72.15)	0.00
Graybug Vision	$426.96 million	0.00	-$35.60 million	($24.23)	-0.02

Graybug Vision has higher revenue and earnings than Hepion Pharmaceuticals. Graybug Vision is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hepion Pharmaceuticals and Graybug Vision’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Graybug Vision	N/A	-77.61%	-71.34%

Institutional & Insider Ownership

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Summary

Graybug Vision beats Hepion Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.